Pharmacogenomics (PGx) represents a potentially powerful enhancement to the current standard of care. Positive impacts can be realized by patients, healthcare providers, payers, and researchers contingent on clinically useful insights into medication response and adverse events. However, a variety of technical, regulatory, and implementation challenges must be addressed in order to provide real-world clinical decision support for personalized prescribing based on genomic data. While the last ten years have provided improvements, policy changes, and learnings from implementations of pharmacogenomics, we are now living in a unique time where technology, regulatory policy, payer policy, and medically-relevant and clinically-actionable science are aligned to support rational healthcare implementations.
In this Research Topic, we will cover new developments in the field of pharmacogenomics ranging from basic science to translational implementations. Embracing the idea of “bench to bedside and back,” we welcome original research, reviews, opinions, and perspectives related to any one or more of the following themes:
• Multigenetic/genomic markers of medication response and/or adverse events;
• Polygenic response scores and pharmacokinetic and/or pharmacodynamic pathways of medications (xenobiotics);
• Pharmacogenomic technology including genotyping/sequencing instrumentation, pharmacogenomic-based clinical decision support tools, and electronic health records;
• Regulatory Oversight and Reimbursement;
• Rational, real-world implementations of pharmacogenomics in healthcare;
• Current state and the future of pharmacogenomics.
Dr. Shaman is Chief Officer at Coriell Life Sciences. Dr. Mitropoulou is the managing director of the Golden Helix Foundation. The other Topic Editors declare no conflict of interest in relation to the Research Topic theme
Pharmacogenomics (PGx) represents a potentially powerful enhancement to the current standard of care. Positive impacts can be realized by patients, healthcare providers, payers, and researchers contingent on clinically useful insights into medication response and adverse events. However, a variety of technical, regulatory, and implementation challenges must be addressed in order to provide real-world clinical decision support for personalized prescribing based on genomic data. While the last ten years have provided improvements, policy changes, and learnings from implementations of pharmacogenomics, we are now living in a unique time where technology, regulatory policy, payer policy, and medically-relevant and clinically-actionable science are aligned to support rational healthcare implementations.
In this Research Topic, we will cover new developments in the field of pharmacogenomics ranging from basic science to translational implementations. Embracing the idea of “bench to bedside and back,” we welcome original research, reviews, opinions, and perspectives related to any one or more of the following themes:
• Multigenetic/genomic markers of medication response and/or adverse events;
• Polygenic response scores and pharmacokinetic and/or pharmacodynamic pathways of medications (xenobiotics);
• Pharmacogenomic technology including genotyping/sequencing instrumentation, pharmacogenomic-based clinical decision support tools, and electronic health records;
• Regulatory Oversight and Reimbursement;
• Rational, real-world implementations of pharmacogenomics in healthcare;
• Current state and the future of pharmacogenomics.
Dr. Shaman is Chief Officer at Coriell Life Sciences. Dr. Mitropoulou is the managing director of the Golden Helix Foundation. The other Topic Editors declare no conflict of interest in relation to the Research Topic theme
